Íomhá chlúdaigh

Efectividad de la vacuna BNT162b2 en el personal del Centro de Salud de Jávea

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	María José Mulet Pons (Údar), Gustavo Silva Paredes (Údar)
Formáid:	LEABHAR
Foilsithe / Cruthaithe:	Elsevier, 2022-01-01T00:00:00Z.
Ábhair:	article
Rochtain ar líne:	Connect to this object online.
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Reactive arthritis following COVID-19 vaccination with BNT162b2
de réir: Emily Lebowitz, MD, et al.
Foilsithe / Cruthaithe: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
de réir: Francesca Fortunato, et al.
Foilsithe / Cruthaithe: (2023)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
de réir: Hazal Cansu Çulpan, et al.
Foilsithe / Cruthaithe: (2023)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
de réir: Chi-Yan Lam, et al.
Foilsithe / Cruthaithe: (2023)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
de réir: Yohhei Hamada
Foilsithe / Cruthaithe: (2021)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
de réir: Mitsuhiro Nagano, et al.
Foilsithe / Cruthaithe: (2024)

BNT162b2 mRNA Vaccine-Induced Immune Response in Oral Fluids and Serum
de réir: Chaminda Jayampath Seneviratne, et al.
Foilsithe / Cruthaithe: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
de réir: Gili Regev-Yochay, et al.
Foilsithe / Cruthaithe: (2021)

B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
de réir: Younes Bathish, et al.
Foilsithe / Cruthaithe: (2024)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer-BioNTech) COVID‐19 vaccination
de réir: Akihiro Matsubara, et al.
Foilsithe / Cruthaithe: (2021)

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
de réir: Shanti Pather, et al.
Foilsithe / Cruthaithe: (2023)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
de réir: Bei Wang, et al.
Foilsithe / Cruthaithe: (2021)

BNT162b2 immunization-related myocarditis in adolescents and consequent hospitalization: Report from a medical center
de réir: Chen-Wei Yen, et al.
Foilsithe / Cruthaithe: (2023)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
de réir: Rumiko Shimazawa, et al.
Foilsithe / Cruthaithe: (2021)

Effectiveness of BNT162b2 COVID-19 vaccine among healthcare workers of a large hospital, Milan, Italy
de réir: Dario Consonni, et al.
Foilsithe / Cruthaithe: (2022)

Short-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study
de réir: Sami Abdeen, et al.
Foilsithe / Cruthaithe: (2024)

Technical note: The calculated real world BNT162b2 vaccine efficacy was 88% when accounting for asymptomatic cases
de réir: Richard Paul Junghans
Foilsithe / Cruthaithe: (2021)

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
de réir: Frank van den Ouweland, et al.
Foilsithe / Cruthaithe: (2024)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
de réir: Michael Kwan Leung Yu, et al.
Foilsithe / Cruthaithe: (2024)

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
de réir: Jose W. Ricardo, MD, et al.
Foilsithe / Cruthaithe: (2021)

BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
de réir: Shir Azrielant, et al.
Foilsithe / Cruthaithe: (2024)

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
de réir: Angel Paternina-Caicedo, et al.
Foilsithe / Cruthaithe: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
de réir: Ai-Min Hui, et al.
Foilsithe / Cruthaithe: (2022)

Allergy to PEG (polyethylene glycol) - sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2
de réir: Bernadette Eberlein, et al.
Foilsithe / Cruthaithe: (2024)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
de réir: Salvatore Zaffina, et al.
Foilsithe / Cruthaithe: (2021)

Coincidence of BNT162b2 mRNA COVID-19 vaccination and hashimoto thyroiditis presenting as atrioventricular block: Causality or casualty
de réir: Kuang-Jen Chien, et al.
Foilsithe / Cruthaithe: (2023)

Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes
de réir: Hamdi Cihan Emeksiz, et al.
Foilsithe / Cruthaithe: (2023)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
de réir: Giulia Vivaldi, et al.
Foilsithe / Cruthaithe: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
de réir: Suvimol Niyomnaitham, et al.
Foilsithe / Cruthaithe: (2022)

Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2
de réir: Ortloff, Andrea, et al.
Foilsithe / Cruthaithe: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
de réir: Xiaotian Wu, MBBS, MRCP, MMed, et al.
Foilsithe / Cruthaithe: (2022)

Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis
de réir: Tingting Li, et al.
Foilsithe / Cruthaithe: (2022)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
de réir: Toshio Naito, et al.
Foilsithe / Cruthaithe: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
de réir: Andrea Lombardi, et al.
Foilsithe / Cruthaithe: (2021)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
de réir: Rana Shibli, et al.
Foilsithe / Cruthaithe: (2021)

Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
de réir: Clara Udaondo, et al.
Foilsithe / Cruthaithe: (2022)

Efectividad comunitaria de las vacunas frente a la Parotiditis Infecciosa. Estudio de casos
de réir: Limón Mora Juan, et al.
Foilsithe / Cruthaithe: (1999)

Efectividad a corto plazo de la vacuna antipertusis en adolescentes: revisión sistemática
de réir: Carmen Niño-Ruiz, et al.

COVID-19 mRNA BNT162b2 vaccine safety and antibodies level among healthcare workers at Centre Hospitalier du Nord
de réir: Rosabelle Chedid, et al.
Foilsithe / Cruthaithe: (2022)

Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
de réir: Pedro Rodríguez-Jiménez, MD, PhD, et al.
Foilsithe / Cruthaithe: (2021)